At the upcoming ASCO meeting, a separate biomarker analysis will be presented that explored how the ipilimumab/nivolumab combination may overcome factors that appear to inhibit patient response to monotherapy with either treatment.
Wolchok said that the combination is also being examined in patients with non–small cell lung cancer and renal cancer.
Wolchok JD, Kluger HM, Callahan MK, et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). J Clin Oncol. 2013;(suppl; abstr 9012).
<<< View more from the 2013 ASCO Annual Meeting